Richard Nolan Townsend Sells 3,342 Shares of Lexeo Therapeutics (NASDAQ:LXEO) Stock

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Richard Nolan Townsend sold 3,342 shares of the company’s stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $5.06, for a total transaction of $16,910.52. Following the completion of the sale, the chief executive officer owned 336,764 shares in the company, valued at approximately $1,704,025.84. This trade represents a 0.98% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Richard Nolan Townsend also recently made the following trade(s):

• On Monday, April 6th, Richard Nolan Townsend sold 55,000 shares of Lexeo Therapeutics stock. The shares were sold at an average price of $5.69, for a total transaction of $312,950.00.

Lexeo Therapeutics Stock Performance

Shares of Lexeo Therapeutics stock opened at $5.23 on Friday. The firm has a market cap of $410.66 million, a PE ratio of -3.61 and a beta of 1.52. The firm’s 50-day simple moving average is $5.92 and its 200-day simple moving average is $7.53. Lexeo Therapeutics, Inc. has a 1 year low of $2.51 and a 1 year high of $10.99.

Lexeo Therapeutics (NASDAQ:LXEO) last issued its earnings results on Monday, May 11th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.04. On average, equities analysts predict that Lexeo Therapeutics, Inc. will post -1.19 earnings per share for the current year.

Institutional Investors Weigh In On Lexeo Therapeutics

A number of institutional investors have recently modified their holdings of LXEO. Allworth Financial LP grew its position in Lexeo Therapeutics by 1,002.9% in the 4th quarter. Allworth Financial LP now owns 3,386 shares of the company’s stock worth $34,000 after purchasing an additional 3,079 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in Lexeo Therapeutics by 69.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,547 shares of the company’s stock worth $35,000 after purchasing an additional 1,459 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new position in Lexeo Therapeutics in the 4th quarter worth about $37,000. California State Teachers Retirement System grew its position in Lexeo Therapeutics by 123.7% in the 4th quarter. California State Teachers Retirement System now owns 3,884 shares of the company’s stock worth $39,000 after purchasing an additional 2,148 shares during the last quarter. Finally, Cerity Partners LLC bought a new position in Lexeo Therapeutics in the 2nd quarter worth about $50,000. Institutional investors own 60.67% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on LXEO. Wall Street Zen raised shares of Lexeo Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Chardan Capital reaffirmed a “buy” rating and set a $17.00 price objective on shares of Lexeo Therapeutics in a research report on Monday, May 11th. Finally, Weiss Ratings raised shares of Lexeo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 15th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Lexeo Therapeutics has an average rating of “Moderate Buy” and an average price target of $18.88.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.